SCHEMBL3955797

SCHEMBL3955797

CCOC(=O)CCC(=O)C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.48
GAA P10253 2/20 0.48
MGAM O43451 1/20 0.48
SI P14410 1/20 0.48
MGAM2 Q2M2H8 1/20 0.48
ALDH1A1 P00352 5/20 0.44
TRPA1 O75762 1/20 0.44
POLB P06746 3/20 0.42
LMNA P02545 2/20 0.42
TSHR P16473 2/20 0.42
CYP4F2 P78329 2/20 0.40
CYP4A11 Q02928 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NR1I2 O75469 1/20 0.39
PGR P06401 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
PTGS2 P35354 1/20 0.39
PDE4D Q08499 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HSD17B10 Q99714 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16017854 0.86 ADRA2A (0.39) CYP1A2ALDH1A1LMNATSHRKMT2A
SCHEMBL13947771 0.83 CYP1A2 (0.45) CYP1A2GAAMGAMSIMGAM2
SCHEMBL18406966 0.83 DGKA (0.45) ALDH1A1LMNAL3MBTL1TDP1
Succinic Acid Diethyl Ester SCHEMBL27768067 0.83 GAA (0.67) CYP1A2GAAMGAMSIMGAM2
Succinic Acid Diethyl Ester SCHEMBL22780 0.83 GAA (0.67) CYP1A2GAAMGAMSIMGAM2
SCHEMBL16017851 0.80 ADRA2A (0.35) TSHRKMT2A
SCHEMBL3603910 0.80 FAAH (0.48) CYP1A2GAAMGAMSIMGAM2
Succinic Acid Diethyl Ester SCHEMBL4324913 0.80 GAA (0.63) CYP1A2GAAMGAMSIMGAM2
Succinic Acid Diethyl Ester SCHEMBL21815758 0.80 GAA (0.63) CYP1A2GAAMGAMSIMGAM2
Succinic Acid Diethyl Ester SCHEMBL28853161 0.80 GAA (0.63) CYP1A2GAAMGAMSIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) 2023-11-02 US disclosed
US-20230056284-A1 EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY Graybug Vision, Inc. (US) 2023-02-23 US disclosed
US-20230058971-A1 EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY Graybug Vision, Inc. (US) 2023-02-23 US disclosed
US-20200230246-A1 EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY Graybug Vision, Inc. (US) 2020-07-23 US disclosed
US-9725436-B2 Cytochrome P450 inhibitors and their method of use CORTENDO AB (PUBL) (US) 2017-08-08 US disclosed
US-20160221990-A1 NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE HAYFIN SERVICES LLP (GB) 2016-08-04 US disclosed
US-20130029967-A1 Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2013-01-31 US disclosed
US-20090280977-A1 PROCESS FOR PREPARING CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS BASELL POLIOLEFINE ITALIA S.R.L (IT) 2009-11-12 US disclosed
EP-2051999-A1 PROCESS FOR PREPARING CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS Basell Poliolefine Italia S.r.l. (IT) 2009-04-29 EP disclosed
WO-2008019802-A1 PROCESS FOR PREPARING CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS BASELL POLIOLEFINE ITALIA S.R.L. (DE) 2008-02-21 WO disclosed
US-5849654-A Catalyst for olefin polymerization and process for producing polyolefin using the same JAPAN POLYOLEFINS CO., LTD. (JP) 1998-12-15 US disclosed
EP-0849291-A1 Catalyst for olefin polymerization and method for preparing polyolefins Japan Polyolefins Co., Ltd. (JP) 1998-06-24 EP disclosed
US-5693729-A STEREOSPECIFIC CATALYZING IN PRESENCE OF A MIXTURE CONSISTING OF A TITANIUM AND A MAGNESIUM COMPOUND, AN ORGANOALUMINUM COMPOUND OR AN ALUMOXANE, AN ORGANOSILICON COMPOUND SHOWA DENKO K.K. (JP) 1997-12-02 US disclosed
EP-0578473-B1 Catalyst for polymerization of olefin and process for producing olefin polymer SHOWA DENKO KK (JP) 1997-11-19 EP disclosed
EP-0640624-B1 Catalyst for polymerization of olefin and process for the preparation of olefin polymer SHOWA DENKO KK (JP) 1997-06-18 EP disclosed
EP-0717053-A2 Catalyst for olefin polymerization and process for producing polyolefin using the same JAPAN POLYOLEFINS CO., LTD. (JP) 1996-06-19 EP disclosed
US-5476825-A Consists of magnesium, titanium and halogen compounds, an organoaluminum compound, a reaction product of organoaluminum or organoboron compound with organosilicon compound SHOWA DENKO K.K. (JP) 1995-12-19 US disclosed
US-5407883-A Containing magnesium, titanium, aluminum and silicon compounds including polymeric aluminum and alumoxanes SHOWA DENKO K.K. (JP) 1995-04-18 US disclosed
EP-0640624-A1 Catalyst for polymerization of olefin and process for the preparation of olefin polymer SHOWA DENKO KABUSHIKI KAISHA (JP) 1995-03-01 EP disclosed
EP-0578473-A1 Catalyst for polymerization of olefin and process for producing olefin polymer SHOWA DENKO KABUSHIKI KAISHA (JP) 1994-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF GRIN1, GRIN3A, GRIN2C CYP1A2 3272/4885GAA 2657/4885MGAM 1794/4885
US-20130029967-A1 Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors MTOR, PIK3CA, CDK2 CYP1A2 923/4885GAA 3022/4885MGAM 3125/4885
US-20230058971-A1 EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY CHMP4B, EXOSC9, EXOSC5 CYP1A2 2730/4885GAA 907/4885MGAM 439/4885
US-20200230246-A1 EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY CHMP4B, EXOSC9, EXOSC5 CYP1A2 2730/4885GAA 907/4885MGAM 439/4885
US-20230056284-A1 EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY CHMP4B, EXOSC9, EXOSC5 CYP1A2 2730/4885GAA 907/4885MGAM 439/4885
US-20160221990-A1 NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE CYP11B1, CYP11B2, CYP21A2 CYP1A2 29/4885GAA 459/4885MGAM 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.